WO2024252368A3 - Procédés et compositions pour le traitement de la rectocolite hémorragique - Google Patents

Procédés et compositions pour le traitement de la rectocolite hémorragique Download PDF

Info

Publication number
WO2024252368A3
WO2024252368A3 PCT/IB2024/055621 IB2024055621W WO2024252368A3 WO 2024252368 A3 WO2024252368 A3 WO 2024252368A3 IB 2024055621 W IB2024055621 W IB 2024055621W WO 2024252368 A3 WO2024252368 A3 WO 2024252368A3
Authority
WO
WIPO (PCT)
Prior art keywords
ulcerative colitis
methods
compositions
treating ulcerative
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2024/055621
Other languages
English (en)
Other versions
WO2024252368A2 (fr
Inventor
Maria PARASKEVOPOULOU
Eleonora A.M. FESTEN
Emilia BIGAEVA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of WO2024252368A2 publication Critical patent/WO2024252368A2/fr
Publication of WO2024252368A3 publication Critical patent/WO2024252368A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des procédés et des compositions associés à des procédés pour déterminer si un sujet humain ayant une rectocolite hémorragique répondra à un traitement avec un anticorps humanisé ayant une spécificité de liaison pour l'intégrine α4β7 humaine afin de traiter la rectocolite hémorragique. L'invention concerne des marqueurs de réponse qui peuvent être utilisés pour identifier des sujets répondeurs atteints de colite ulcéreuse.
PCT/IB2024/055621 2023-06-09 2024-06-08 Procédés et compositions pour le traitement de la rectocolite hémorragique Ceased WO2024252368A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363507369P 2023-06-09 2023-06-09
US63/507,369 2023-06-09
US202363590182P 2023-10-13 2023-10-13
US63/590,182 2023-10-13

Publications (2)

Publication Number Publication Date
WO2024252368A2 WO2024252368A2 (fr) 2024-12-12
WO2024252368A3 true WO2024252368A3 (fr) 2025-02-13

Family

ID=91664853

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2024/055621 Ceased WO2024252368A2 (fr) 2023-06-09 2024-06-08 Procédés et compositions pour le traitement de la rectocolite hémorragique

Country Status (1)

Country Link
WO (1) WO2024252368A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法
CN121754644A (zh) * 2026-03-04 2026-03-31 苏州大学 Cxcl14重组蛋白在制备预防或治疗放射性肠炎药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220364171A1 (en) * 2018-11-23 2022-11-17 Katholieke Universiteit Leuven Predicting a treatment response in inflammatory bowel disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
WO1989007142A1 (fr) 1988-02-05 1989-08-10 Morrison Sherie L Anticorps a region constante a modification de domaine
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
WO1996024673A1 (fr) 1995-02-10 1996-08-15 Leukosite, Inc. Adressines vasculaires de muqueuses et leurs utilisations
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
WO2006026759A2 (fr) 2004-09-03 2006-03-09 Genentech, Inc. Antagonistes anti-beta7 humanises et utilisations de ceux-ci
EP1948691A1 (fr) 2005-11-17 2008-07-30 Millennium Pharmaceuticals, Inc. IMMUNOGLOBULINE HUMANISEE REACTIVE AVEC L INTEGRINE a4ß7
CN103382222B (zh) 2009-03-20 2016-12-28 安姆根有限公司 α-4-β-7异二聚体特异性拮抗剂抗体
MX367097B (es) 2011-05-02 2019-08-05 Millennium Pharm Inc FORMULACION PARA ANTICUERPO ANTI-A4ß7.
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220364171A1 (en) * 2018-11-23 2022-11-17 Katholieke Universiteit Leuven Predicting a treatment response in inflammatory bowel disease

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ARIJS INGRID ET AL: "Effect of vedolizumab (anti-[alpha]4[beta]7-integrin) therapy on histological healing and mucosal gene expression in patients with UC", GUT MICROBIOTA, vol. 67, no. 1, 7 October 2016 (2016-10-07), UK, pages 43 - 52, XP093234548, ISSN: 0017-5749, Retrieved from the Internet <URL:https://gut.bmj.com/content/gutjnl/67/1/43.full.pdf> DOI: 10.1136/gutjnl-2016-312293 *
DE GALAN CARA ET AL: "Role of integrin expression in the prediction of response to?vedolizumab: A prospective real-life multicentre cohort?study", CLINICAL AND TRANSLATIONAL MEDICINE, vol. 12, no. 4, 1 April 2022 (2022-04-01), SE, XP093203941, ISSN: 2001-1326, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1002/ctm2.769> DOI: 10.1002/ctm2.769 *
FESTEN ELEONORA ET AL: "High-dimensional single-cell analysis identifies cellular signatures associated with response to vedolizumab therapy in ulcerative colitis", RESEARCH SQUARE, 12 September 2023 (2023-09-12), XP093204249, Retrieved from the Internet <URL:https://www.researchgate.net/publication/374408119_High-dimensional_single-cell_analysis_identifies_cellular_signatures_associated_with_response_to_vedolizumab_therapy_in_ulcerative_colitis> DOI: 10.21203/rs.3.rs-3348629/v1 *
GAZOULI MARIA ET AL: "Response to Anti-[alpha]4[beta]7 Blockade in Patients With Ulcerative Colitis Is Associated With Distinct Mucosal Gene Expression Profiles at Baseline", HHS PUBLIC ACCESS AUTHOR MANUSCRIPT, vol. 28, no. 1, 27 May 2021 (2021-05-27), US, pages 87 - 95, XP093205166, ISSN: 1078-0998, Retrieved from the Internet <URL:https://academic.oup.com/ibdjournal/article-pdf/28/1/87/45808475/izab117.pdf> DOI: 10.1093/ibd/izab117 *
HSU PAUL ET AL: "Responsiveness to Vedolizumab Therapy in Ulcerative Colitis is Associated With Alterations in Immune Cell-Cell Communications", HHS PUBLIC ACCESS AUTHOR MANUSCRIPT, vol. 29, no. 10, 26 May 2023 (2023-05-26), US, pages 1602 - 1612, XP093204254, ISSN: 1078-0998, Retrieved from the Internet <URL:https://academic.oup.com/ibdjournal/article-pdf/29/10/1602/51840044/izad084.pdf> DOI: 10.1093/ibd/izad084 *
KARMI N. ET AL: "Single-cell analysis of gut mucosal- and peripheral blood cells in ulcerative colitis patients undergoing vedolizumab treatment", JOURNAL OF CROHN'S AND COLITIS, vol. 16, no. Suppl 1, 1 January 2022 (2022-01-01), pages i153 - i154, XP093204251, Retrieved from the Internet <URL:https://academic.oup.com/ecco-jcc/article/16/Supplement_1/i153/6512476> *
PIBIRI P ET AL: "Abstract citation ID: jjac190.0005 OP05 High-dimensional single-cell analysis identifies cellular signatures associated with response to vedolizumab therapy in ulcerative colitis", 30 January 2023 (2023-01-30), XP093234538, Retrieved from the Internet <URL:https://watermark.silverchair.com/jjac190.0005.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAA5IwggOOBgkqhkiG9w0BBwagggN_MIIDewIBADCCA3QGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMscteDltrd0HBTk-PAgEQgIIDRQH-caDIvE1HbcyUGsA1c2DzgZSrM3Mpxv7MnNUuc8B7R1Oay0MEx_wuQp90JL5sI25Aweg75yzUKE92emZJF_g> *
VERSTOCKT BRAM ET AL: "Expression Levels of 4 Genes in Colon Tissue Might Be Used to Predict Which Patients Will Enter Endoscopic Remission After Vedolizumab Therapy for Inflammatory Bowel Diseases", CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 18, no. 5, 22 August 2019 (2019-08-22), pages 1142, XP086134038, ISSN: 1542-3565, [retrieved on 20190822], DOI: 10.1016/J.CGH.2019.08.030 *
WEI KEVIN ET AL: "Fibroblast pathology in inflammatory diseases", JOURNAL OF CLINICAL INVESTIGATION, vol. 131, no. 20, 15 October 2021 (2021-10-15), XP093044940, Retrieved from the Internet <URL:https://dm5migu4zj3pb.cloudfront.net/manuscripts/149000/149538/cache/149538.1-20211006180935-covered-e0fd13ba177f913fd3156f593ead4cfd.pdf> DOI: 10.1172/JCI149538 *

Also Published As

Publication number Publication date
WO2024252368A2 (fr) 2024-12-12

Similar Documents

Publication Publication Date Title
WO2024252368A3 (fr) Procédés et compositions pour le traitement de la rectocolite hémorragique
Cirino et al. Longitudinal predictors of the overlap between reading and math skills
MA54261A (fr) Inhibiteurs de pcsk9 et leurs procédés d&#39;utilisation
EP3911640A4 (fr) Inhibiteurs de pcsk9 et leurs procédés d&#39;utilisation
DE60219801D1 (de) KOMPLEMENT-INHIBITOREN DIE AN C5 UND C5a BINDEN OHNE DIE BILDUNG VON C5b ZU HEMMEN
MA52753A (fr) Anticorps anti-sirpa et leurs procédés d&#39;utilisation
EP3977651A4 (fr) Systèmes et procédés de filigranage du temps, du lieu et de l&#39;identité d&#39;événements
BR112018014146A2 (pt) métodos de teste rápido de suscetibilidade antimicrobiana
MA55025A (fr) Anticorps anti-trem2 et leurs procédés d&#39;utilisation
EP3509637A4 (fr) Procédés d&#39;utilisation d&#39;un anticorps bispécifique qui reconnaît le facteur de coagulation ix et/ou le facteur de coagulation ix activé et le facteur de coagulation x et/ou le facteur de coagulation x activé
EP3962479A4 (fr) Inhibiteurs de kcnt1 et procédés d&#39;utilisation
EP3962481A4 (fr) Inhibiteurs de kcnt1 et procédés d&#39;utilisation
MA54955A (fr) Anticorps anti-claudine 6 et leurs utilisations
MA51837A (fr) Inhibiteurs de l&#39;arginase et leurs procédés d&#39;utilisation
EP3953385A4 (fr) Anticorps cd19 et leurs procédés d&#39;utilisation
EP4284365A4 (fr) Inhibiteurs de cdk2 et leurs procédés d&#39;utilisation
MA51207A (fr) Anticorps monoclonaux anti-trkb et leurs procédés d&#39;utilisation
EP3938785A4 (fr) Utilisation de nanoparticules magnétiques pour la détection et la quantification d&#39;un ou de plusieurs analytes
EP4144859A4 (fr) Réactif de détection de tumeur et kit
Caillon et al. Overcoming the interference of daratumumab with immunofixation electrophoresis (IFE) using an industry-developed dira test: hydrashift 2/4 daratumumab
EA202190056A1 (ru) АНТИТЕЛА ПРОТИВ ФАКТОРА XII/XIIa И ИХ ПРИМЕНЕНИЕ
Killackey Resignation not accepted: employment, education and training in early intervention, past, present and future.
EP3997121A4 (fr) Anticorps reconnaissant spécifiquement pcrv de pseudomonas et leurs utilisations
DE60024809D1 (de) Verwendung von anti-hbp antikörper zur inhibierung der freisetzung von bradykinin
EP3956448A4 (fr) Inhibiteurs de aim2 et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24736079

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE